BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24819973)

  • 1. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
    Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2019 Feb; 41(1):86-90. PubMed ID: 30489548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study.
    Nagai G; Mihara K; Kagawa S; Nakamura A; Suzuki T; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 76(4):187-192. PubMed ID: 29961057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
    Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
    Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study.
    Kikkawa A; Kitamura Y; Aiba T; Hiraki K; Sendo T
    Biol Pharm Bull; 2017; 40(4):413-418. PubMed ID: 28381796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
    Schindler F; Anghelescu IG
    Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A factor analytic study in bipolar depression, and response to lamotrigine.
    Mitchell PB; Hadzi-Pavlovic D; Evoniuk G; Calabrese JR; Bowden CL
    CNS Spectr; 2013 Aug; 18(4):214-24. PubMed ID: 23702258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
    Gabriel A
    Depress Anxiety; 2006; 23(8):485-8. PubMed ID: 16845646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression].
    Krawczyk K; Rybakowski J
    Psychiatr Pol; 2012; 46(4):585-98. PubMed ID: 23214161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.
    Bares M; Novak T; Kopecek M; Stopkova P; Cermak J; Kozeny J; Höschl C
    Int J Psychiatry Clin Pract; 2013 Feb; 17(1):35-43. PubMed ID: 22486580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
    Anand A; Gunn AD; Barkay G; Karne HS; Nurnberger JI; Mathew SJ; Ghosh S
    Bipolar Disord; 2012 Feb; 14(1):64-70. PubMed ID: 22329473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.
    Calabrese JR; Huffman RF; White RL; Edwards S; Thompson TR; Ascher JA; Monaghan ET; Leadbetter RA
    Bipolar Disord; 2008 Mar; 10(2):323-33. PubMed ID: 18271912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.
    Chang JS; Moon E; Cha B; Ha K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1322-6. PubMed ID: 20673782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study.
    Christensen J; Sandgaard AP; Sidenius P; Linnet K; Licht RW
    Pharmacopsychiatry; 2012 May; 45(3):119-21. PubMed ID: 22426846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
    Kremer I; Vass A; Gorelik I; Bar G; Blanaru M; Javitt DC; Heresco-Levy U
    Biol Psychiatry; 2004 Sep; 56(6):441-6. PubMed ID: 15364042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.